The IL-23/IL-17 axis as a therapeutic target

Japanese Journal of Clinical Immunology

Volumn 36, Issue 4, 2013, Pages 203-208

  Sato, Kojiro ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

IL 17; IL 23; Th17; Ustekinumab

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 23;

AUTOINFLAMMATORY DISEASE; HUMAN; NONHUMAN; PSORIASIS; REVIEW; TH17 CELL;

ANIMALS; CELL DIFFERENTIATION; HUMANS; INTERLEUKIN-17; INTERLEUKIN-23; MOLECULAR TARGETED THERAPY; TH17 CELLS;

EID: 84883407518     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.36.203     Document Type: Review

References (51)

1. Mosmann, T.R., et al.: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136: 2348-2357, 1986.
2. Smolen, J.S., et al.: The role of T-lymphocytes and cytokines in rheumatoid arthritis. Scand J Rheumatol 25: 1-4, 1996.
3. Manoury-Schwartz, B., et al.: High susceptibility to collagen-induced arthritis in mice lacking IFN-g receptors. J Immunol 158: 5501-5506, 1997.
4. Vermeire, K., et al.: Accelerated collagen-induced arthritis in IFN-g receptor-deficient mice. J Immunol 158: 5507-5513, 1997.
5. Guedez, Y.B., et al.: Genetic ablation of interferon-gamma up-regulates interleukin-1beta expression and enables the elicitation of collageninduced arthritis in a nonsusceptible mouse strain. Arthritis Rheum 44: 2413-2424, 2001.
6. Billiau, A., et al.: Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma. J Immunol 140: 1506-1510, 1988.
7. Ferber, I.A., et al.: Mice with a disrupted IFNgamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 156: 5-7, 1996.
8. Krakowski, M., Owens, T.: Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur J Immunol 26: 1641-1646, 1996.
9. Voorthuis, J.A., et al.: Suppression of experimental allergic encephalomyelitis by intraventricular administration of interferongamma in Lewis rats. Clin Exp Immunol 81: 183-188, 1990.
10. Willenborg, D.O., et al.: IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol 157: 3223-3227, 1996.
11. Harrington, L.E., et al.: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6: 1123-1132, 2005.
12. Park, H., et al.: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6: 1133-1141, 2005.
13. Oppmann, B., et al.: Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13: 715-725, 2000.
14. Cua, D.J., et al.: Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744-748, 2003.
15. Aggarwal, S., et al.: Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 278: 1910-1914, 2003.
16. Kotake, S., et al.: IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103: 1345-1352, 1999.
17. Bettelli, E., et al.: Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 441: 235-238, 2006.
18. Mangan, P.R., et al.: Transforming growth factor-b induces development of the Th17 lineage. Nature 441: 231-234, 2006.
19. Acosta-Rodriguez, E.V., et al.: Interleukins 1b and 6 but not transforming growth factor-b are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 8: 942-949, 2007.
20. Wilson, N.J., et al.: Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8: 950-957, 2007.
21. Manel, N., et al.: The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 9: 641-649, 2008.
22. Volpe, E., et al.: A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol 9: 650-657, 2008.
23. McGeachy, M.J., et al.: TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 8: 1390-1397, 2007.
24. Ivanov, I.I., et al.: The orphan nuclear receptor RORgt directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126: 1121-1133, 2006.
25. Kimura, A., et al.: Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Natl Acad Sci USA 105: 9721-9726, 2008.
26. Veldhoen, M., et al.: The aryl hydrocarbon receptor links Th17-cell-mediated autoimmunity to environmental toxins. Nature 453: 106-109, 2008.
27. Infante-Duarte, C., et al.: Microbial lipopeptides induce the production of IL-17 in Th cells. J Immunol 165: 6107-6115, 2000.
28. Miossec, P., et al.: Interleukin-17 and type 17 helper T cells. N Engl J Med 361: 888-898, 2009.
29. Ye, P., et al.: Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 194: 519-527, 2001.
30. Huang, W., et al.: Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 190: 624-631, 2004.
31. Nakae, S., et al.: Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 171: 6173-6177, 2003.
32. Genovese, M.C., et al.: LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-ofconcept study. Arthritis Rheum 62: 929-939, 2010.
33. Grieffiths, C.E., et al.: Comparison of ustekinumab and etanercept for moderate-tosevere psoriasis. N Engl J Med 362: 118-128, 2010.
34. Lee, E., et al.: Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 199: 125-130, 2004.
35. Johnson-Huang, L.M., et al.: Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. J Invest Dermatol 130: 2654-2663, 2010.
36. Zaba, L.C., et al.: Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 204: 3183-3194, 2007.
37. Chan, J.R., et al.: IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 203: 2577-2587, 2006.
38. Zheng, Y., et al.: Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal in-flammation and acanthosis. Nature 445: 648-651, 2007.
39. Papp, K.A., et al.: Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 366: 1181-1189, 2012.
40. Leonardi, C., et al.: Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl JMed 366: 1190-1199, 2012.
41. Solt, L.A., et al.: Suppression of Th17 differentiation and autoimmunity by a synthetic ROR ligand. Nature 472: 491-494, 2011.
42. Huh, J.R., et al.: Digoxin and its derivatives suppress Th17 cell differentiation by antagonizing RORgammat activity. Nature 472: 486-490, 2011.
43. Hueber, A.J., et al.: Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 184: 3336-3340, 2010.
44. Suurmond, J., et al.: Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and-negative rheumatoid arthritis and osteoarthritis synovium. Arthritis Res Ther 13: R150, 2011.
45. Roark, C.L., et al.: gammadelta T cells: an important source of IL-17. Curr Opin Immunol 20: 353-357, 2008.
46. Cai, Y., et al.: Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity 35: 596-610, 2011.
47. Pantelyushin, S., et al.: Rorgammat+ innate lymphocytes and gammadelta T cells initiate psoriasiform plaque formation in mice. J Clin Invest 122: 2252-2256, 2012.
48. Lin, A.M., et al.: Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 187: 490-500, 2011.
49. Sandborn, W.J., et al.: Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 367: 1519-1528, 2012.
50. Hirota, K., et al.: Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol 12: 255-263, 2011.
51. Hirota, K., et al.: Plasticity of Th17 cells in Peyer's patches is responsible for the induction of T cell-dependent IgA responses. Nat Immunol 14: 372-379, 2013.